This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Apollo Endosurgery マネジメント

マネジメント基準チェック /34

主要情報

Chas McKhann

最高経営責任者

US$2.8m

報酬総額

CEO給与比率	19.8%
CEO在任期間	2.1yrs
CEOの所有権	0.4%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	5.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Apollo Endosurgery の収益と比較して、Chas McKhann の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2022	US$3m	US$550k	-US$40m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$9m	US$375k	-US$25m

報酬と市場: Chas's total compensation ($USD2.78M) is above average for companies of similar size in the German market ($USD886.27K).

報酬と収益: Chas's compensation has been consistent with company performance over the past year.

CEO（最高経営責任者

Chas McKhann (53 yo)

2.1yrs

在職期間

US$2,780,544

報酬

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% € 2.1m
Jeffrey Black	CFO, Secretary & Treasurer	1.7yrs	US$1.34m	0.18% € 951.6k
John Molesphini	Executive Vice President of Operations	5yrs	US$662.23k	0.079% € 422.7k
Sergey Kantsevoy	Co-Founder and Innovation Partner	no data	データなし	データなし
Anthony Kalloo	Co-Founder and Innovation Partner	no data	データなし	データなし
Robert Hawes	Co-Founder and Innovation Partner	no data	データなし	データなし
Peter Cotton	Co-Founder and Innovation Partner	18.3yrs	データなし	データなし
Christopher Gostout	Co-Founder & Chief Medical Officer	no data	US$1.16m	0.062% € 331.3k
Sydney Chung	Co-Founder and Innovation Partner	no data	データなし	データなし
Pankaj Pasricha	Co-Founder	18.3yrs	データなし	データなし
John Gillings	Investor Relations Manager	no data	データなし	データなし
Brian Szymczak	Vice President of Legal & Compliance	3.6yrs	データなし	データなし

4.3yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: HQ8F's management team is considered experienced (4.3 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% € 2.1m
John Barr	Independent Chairman of the Board	4.1yrs	US$193.24k	0.051% € 273.8k
Julie Shimer	Independent Director	4.9yrs	US$164.49k	0.038% € 199.9k
Richard McGaughy	Independent Director	11.3yrs	US$165.15k	データなし
William McClellan	Independent Director	8.9yrs	US$169.49k	0.047% € 247.9k
Adrian Park	Member of Scientific Advisory Board	no data	データなし	データなし
Mark Talamini	Member of Scientific Advisory Board	no data	データなし	データなし
Santiago Horgan	Member of Scientific Advisory Board	no data	データなし	データなし
Jay Redan	Member of Scientific Advisory Board	no data	データなし	データなし
Steve McCarus	Member of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Marks	Member of Scientific Advisory Board	no data	データなし	データなし
David Pacitti	Independent Director	5.4yrs	US$159.70k	0.0067% € 35.7k

5.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: HQ8F's board of directors are considered experienced (5.2 years average tenure).

This company listing is no longer active

Apollo Endosurgery マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Apollo Endosurgery, Inc. Announces Board Changes

CEO, President & Director recently sold €432k worth of stock

Recent updates

Full year 2022 earnings released: US$0.98 loss per share (vs US$0.82 loss in FY 2021)

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.23 loss in 3Q 2021)

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.11 loss in 2Q 2021)

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.17 loss in 1Q 2021)

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Apollo Endosurgery, Inc. Announces Board Changes

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold €432k worth of stock

Chief Financial Officer recently bought €186k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Insider recently sold €105k worth of stock

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

New 90-day high: €6.05

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Revenue beats expectations

Insider recently bought €70k worth of stock

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought €121k worth of stock

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: €3.76

New 90-day high: €2.00

Revenue beats expectations

Third quarter 2020 earnings released: US$0.11 loss per share

New 90-day high: €1.51

New 90-day low - €1.13

New 90-day low - €1.20

First half earnings released

Apollo Endosurgery, Inc. announced that it expects to receive $25 million in funding

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34